Rithm Capital shares climbed 6.7% to $9.26 on Friday following a third-quarter performance that outpaced Wall Street expectations. The alternative asset manager posted a significant profit jump, signaling a robust recovery from its second-quarter results as both revenue and earnings per share exceeded consensus forecasts.
Electric vertical takeoff aircraft will soon navigate the congested corridors of Austin, Houston, and Dallas-Fort Worth. Archer Aviation, the California-based startup behind the initiative, aims to bypass traditional gridlock by linking major airports and business districts, provided the firm secures final regulatory clearance from the Federal Aviation Administration.
With December Brent crude settling at $116.72 a barrel—a 3.1% daily gain—global oil markets are reacting sharply to the prospect of a wider conflict. The surge follows warnings from Iran of potential strikes against regional energy infrastructure as the United States bolsters its military presence in the Persian Gulf.
Brent crude surged 3.1% to reach $116.72, hitting a five-month peak after Tehran threatened retaliatory strikes against U.S. and Israeli assets. This geopolitical escalation rattled equity markets, fueling a flight to safety as investors abandoned risk-heavy positions in favor of stable consumer staples and utilities.
A 5.8% drop in Gentex shares on Friday underscored investor anxiety after the electronics supplier trimmed its annual revenue forecast. The stock, now down 11.2% for the year, reflects a broader cooling in the automotive sector as the company struggles to reconcile production declines with bottom-line expectations.
Shareholders of Middlesex Water are set to receive a larger slice of the company’s earnings after the board approved a 5.6% increase in the quarterly dividend. The payout shift bumps the rate from 36 cents to 38 cents per share, reflecting the utility provider’s latest financial adjustment.
A 22% spike in share price greeted Robert Half on Friday, as investors reacted to a third-quarter earnings report that surpassed analyst expectations. The stock reached $46.07 by afternoon trading, extending its year-to-date gains to 70% following a period of renewed hiring activity in the labor market.
Investors pushed SS&C Technologies shares down 5.4% to $84.12 on Friday after the financial software firm issued a conservative revenue forecast. The market reaction signals growing skepticism toward the company's growth trajectory as it struggles to meet the high expectations set by Wall Street analysts for the coming year.
Global crude freight rates have spiked over $20 per barrel compared to last year, forcing refiners to abandon distant suppliers in favor of local sources. Goldman Sachs analysts warn that this systemic shift is squeezing refinery margins and threatening to drive up the cost of refined products globally.
The Delaware Supreme Court has closed the door on Verisk’s attempt to walk away from its $2.35 billion acquisition of AccuLynx. By affirming an earlier Chancery Court ruling, the state’s highest bench rejected the data analytics giant's claim that it could terminate the deal over a missed regulatory review deadline.
The Department of Energy will release 400,000 barrels of crude oil from the Strategic Petroleum Reserve to mitigate supply disruptions at the Phillips 66 Lake Charles refinery in Louisiana. This exchange agreement aims to maintain production levels of transportation fuels for the state and its surrounding regional markets.
Tango Therapeutics shares dropped 14% to $24.13 on Friday after the company reported tolerability issues in a mid-stage trial for its pancreatic cancer treatment. While the drug combination demonstrated promising efficacy, a specific dosing level triggered significant toxicity concerns among the trial participants.
Novartis shares slumped 4.5% in U.S. trading Friday after new clinical data for its multiple sclerosis pill, remibrutinib, failed to match the efficacy benchmarks set by a competing treatment from Roche. While the drug proved safe, the market reacted to its weaker performance in reducing patient relapse rates.
CTS has finalized its $50 million purchase of Millar Holdings, a strategic move aimed at cementing the manufacturer's footprint within the precision pressure sensing sector. The transaction, which closed Friday, encompasses the assumption of existing debt alongside the acquisition of net cash held by the target firm.
A sharp 7.8% jump in share price greeted First Citizens BancShares on Friday, as the Raleigh-based institution reported a third-quarter profit of $577 million. The surge pushed the stock to $2,368.28, reflecting investor confidence in a performance that comfortably outpaced Wall Street’s expectations for the period.
Patients battling HER2-positive gastroesophageal adenocarcinoma saw survival rates climb following a triple-drug regimen in a Phase 3 study. By combining Tevimbra and Ziihera with standard chemotherapy, BeOne Medicines observed a 40% overall survival rate at the three-year mark, suggesting a potential shift in first-line treatment protocols.
Escalating volatility in the Persian Gulf pushed crude oil futures to a second consecutive day of gains on Friday. With U.S. and Israeli forces weighing renewed strikes against Iran and Iranian leadership threatening retaliation, global markets reacted to the heightened risk of direct attacks on regional energy infrastructure.
Investors pushed Lycia Therapeutics shares to $23.70 on Friday, a 32% gain during the biotechnology firm’s first day of trading. The jump followed an upsized initial public offering that exceeded expectations, effectively securing $317.5 million for the clinical-stage company as it enters the public markets.
Facing a sharp economic downturn and mounting pressure from Chinese rivals, Volkswagen has scheduled high-stakes negotiations with the IG Metall union to begin on November 24. The automaker aims to finalize deep labor cost reductions as it struggles to maintain global competitiveness across its core brands.
Rinatabart sesutecan has cleared key hurdles in a late-stage clinical trial, demonstrating a significant reduction in disease progression among patients with platinum-resistant ovarian cancer. The data from the Phase 3 study marks a pivotal moment for Genmab’s oncology pipeline, sparking a notable rally in the company’s share price.
Shares of Gorman-Rupp jumped 5.9% to $74.31 on Friday, buoyed by a robust third-quarter performance that saw the pump manufacturer double its net profit. Investors responded sharply to the results, which pushed the company’s year-to-date stock gains to 56% following a period of sustained operational growth.
Bristol Myers Squibb has secured a multi-year agreement to leverage the Lens Platform from Tempus AI, integrating the company’s agentic artificial intelligence into its oncology drug development pipeline through 2031. The deal aims to accelerate clinical insights and target discovery by utilizing Tempus’s vast library of real-world multimodal datasets.
Ithaca-based Tompkins Financial is increasing its quarterly dividend to 74 cents per share, a 5.7% hike from the previous 70-cent distribution. This adjustment pushes the company’s annualized payout to $2.96, reflecting a strengthened commitment to shareholder returns following Thursday's closing market price of $100.78.
Wireless giants AT&T, Verizon, and T-Mobile saw shares slide on Friday following reports that Elon Musk’s SpaceX is negotiating a major infrastructure deal with Crown Castle. Securing access to at least 80,000 cell sites across the United States would provide the necessary backbone for a new, nationwide mobile network.
Amid a backdrop of rising profits and increased cardholder spending, American Express announced plans to reduce its global headcount by 5%. The restructuring, affecting roughly 3,800 roles, is intended to flatten the company’s organizational hierarchy and accelerate internal decision-making processes as the firm shifts focus toward long-term innovation.
Fifty-four consecutive years of dividend growth have cemented Gorman-Rupp’s position among the market’s elite. The Mansfield, Ohio-based manufacturer of pumping systems confirmed a 5.3% increase in its quarterly payout, moving from 19 cents to 20 cents per share, signaling a sustained commitment to shareholder returns despite broader economic shifts.
Zai Lab shares climbed 7.3% to $23.65 in Friday premarket trading after the company released promising phase 1 data for its experimental lung cancer therapy. The results, highlighting high tumor response rates in patients with advanced small cell lung cancer, signaled a significant leap for the firm's oncology pipeline.
Shares of Booz Allen Hamilton climbed 5% in premarket trading after the defense contractor beat quarterly earnings expectations and lifted its full-year outlook. Despite a 3.9% dip in revenue to $2.78 billion, the firm reported a second-quarter profit of $181 million, fueled by strong momentum in its national security portfolio.
A $55 million upfront payment has cemented a new strategic alliance between Zymeworks and Roche, tasking the companies with the clinical development of ZW209. This experimental lung cancer therapy now shifts under the global commercialization umbrella of Roche, marking a significant step in Zymeworks’ R&D pipeline strategy.
A report detailing SpaceX’s plans to construct a massive U.S.-wide cellular network has sent shockwaves through the telecommunications sector. As the Elon Musk-led company targets 80,000 cell sites to challenge industry incumbents, investors have moved to dump shares of traditional wireless carriers in anticipation of a new, disruptive competitor.
